Overview: Anti-Mitochondrial Antibody TestIntroduction: The Anti-Mitochondrial Antibody Test detects AMA to diagnose primary biliary cholangitis, causing jaundice or fatigue. Following 2023 AASLD guidelines, it uses immunofluorescence assay for high specificity, supporting liver screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected primary biliary cholangitis.
Other Names: AMA Assay, PBC Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: AMA testing began in the 1960s with autoimmune liver disease research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects AMA to diagnose primary biliary cholangitis, guides treatment, and evaluates patients with jaundice or fatigue.
Test Parameters: 1. Mitochondrial Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of jaundice, fatigue, or liver dysfunction.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, itching, or family history of autoimmune liver diseases. Include current medications, especially ursodiol.
Consent: Written consent required, detailing the tests purpose, primary biliary cholangitis implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence assay to detect AMA in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for PBC diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive AMA confirms primary biliary cholangitis, guiding treatment (e.g., ursodiol). Negative results may require further liver testing.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: Liver function tests, ANA, or liver biopsy to confirm PBC diagnosis.
Test Limitations: Not specific to PBC; other liver diseases may mimic results. Clinical correlation is needed.
References: AASLD PBC Guidelines, 2023; Hepatology, Lindor KD, 2022.
